Aquestive Therapeutics (AQST) Reports Q1 Earnings: What Key Metrics Have to Say

Core Viewpoint - Aquestive Therapeutics reported a significant decline in revenue and earnings for the quarter ended March 2025, indicating potential challenges in financial performance and market expectations [1][3]. Revenue Performance - Total revenue for the quarter was $8.72 million, a decrease of 27.6% compared to the same period last year, and a miss of 28.14% against the Zacks Consensus Estimate of $12.14 million [1]. - Revenue from manufacturing and supply was $7.19 million, falling short of the three-analyst average estimate of $10.07 million, representing a year-over-year decline of 31.6% [4]. - License and royalty revenue amounted to $0.79 million, compared to the average estimate of $1.68 million, reflecting a year-over-year decrease of 30.2% [4]. - Co-development and research fees were reported at $0.42 million, slightly above the two-analyst average estimate of $0.40 million, showing a year-over-year increase of 3.7% [4]. Earnings Performance - The earnings per share (EPS) for the quarter was -$0.24, compared to -$0.17 in the same quarter last year, indicating a worsening in profitability [1]. - The EPS surprise was -41.18% against the consensus estimate of -$0.17 [1]. Stock Performance - Over the past month, shares of Aquestive Therapeutics have returned +13%, outperforming the Zacks S&P 500 composite's +3.8% change [3]. - The stock currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the broader market in the near term [3].